ArticleDermatology and therapy2026

Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).

Luca Potestio et al.PubMed ↗Publisher ↗

No numbers read from the abstract.